Actively Recruiting
Tight Control of Gouty Arthritis Compared to Usual Care
Led by University of Edinburgh · Updated on 2026-04-08
125
Participants Needed
1
Research Sites
185 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Gout is caused by a reaction to urate crystals that results in attacks of severe joint pain. Medicines that lower urate levels can prevent gout flares, however it takes time for this benefit to be felt, and paradoxically starting treatment with large doses of urate lowering treatment risks provoking attacks of gout. Medical guidelines disagree on the best way to overcome these challenges with many recommending medicine dose adjustment based on regular urate testing but a general practice guideline suggesting more simply increasing the medicine dose in those patients that continue to suffer flares. In reality most patients are not treated at all, and many of those that are treated never receive an effective dose of treatment. We have developed a supported self-management approach to gout in which patients monitor their own urate levels using a finger prick test, and then receive advice on adjusting their treatment dose to achieve target urate levels through a smartphone app (Gout SMART). A trial of this approach has shown that it results in much better control of urate levels after 6 months than usual care, and suggests that it also leads to fewer flares. We would now like to confirm that this approach is effective in reducing flares of gout over 2 years by randomising patients to either treatment-to-target urate using our self-monitoring approach, or to usual care.
CONDITIONS
Official Title
Tight Control of Gouty Arthritis Compared to Usual Care
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Provide informed consent
- Age 18 years or older
- Have had at least one gout flare in the previous 12 months
- Confirmed clinical diagnosis of gout according to ACR/EULAR criteria
- Serum urate level greater than 0.36 mmol/L
- Own a smartphone and able to install the GoutSMART application
You will not qualify if you...
- Unable to provide consent
- On maximum urate lowering therapy or unable to increase therapy due to intolerance or adverse reaction to allopurinol or febuxostat
- Have end stage renal failure or received a transplant
- Currently prescribed medications that interact with xanthine oxidase inhibitors such as azathioprine or mercapto-purine
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
NHS Lothian
Edinburgh, United Kingdom
Actively Recruiting
Research Team
P
Philip L Riches, FRCP, PhD
CONTACT
J
Jo-Anne Robertson
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
HEALTH_SERVICES_RESEARCH
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here